Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment

NCT03428958 is registered in ClinicalTrials.gov with NuCana plc as lead sponsor.

NCT NCT03428958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03428958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
Lead sponsor
NuCana plc
Phase
Phase 1/2
Overall status
Completed
Start date
October 5, 2018
Completion date
March 21, 2024
Enrollment
111 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, colorectal carcinoma, colorectal neoplasms, colorectal tumors, neoplasms, colorectal